Financial Markets React to JPMorgan Earnings, Pfizer’s Breast Cancer Breakthrough, and Global Developments

Key TakeawaysJPMorgan Chase & Co. (JPM) reported robust Q3 2025 adjusted revenue of $47.12 billion, exceeding analyst expectations, but its shares experienced a 1% decline following the earnings release despite an upward revision in its full-year 2025 Net Interest Income (NII) forecast to approximately$ 95.8 billion.Pfizer's (PFE) TUKYSA combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with HER2-positive metastatic b ...